Stocks-TTNP-Titan Pharmaceuticals Inc

TTNP Titan Pharmaceuticals Inc

0.7100 -0.0210 (-2.88%)
Delayed Prices By NASDAQ, in USD Market Open
Invest
Invest

FINANCIAL SUMMARY

For the quarter ended 30/9/2022, Titan Pharmaceuticals Inc's revenues decreased by 36.67% and amounted to 95.00K. Net income decreased by 7.15% to -2.64M. Net assets decreased by 37.36% to 3.55M and EPS decreased from -0.18 to -0.18.
TTNP's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
64.34%
Net Profit Margin
-288.02%
Operating Margin
-1,768.01%
Return On Investment
-143.80%